Aditxt, Inc. Overview
Pro stress-test →Aditxt, Inc. is a commercial-stage company that discovers and develops products in immune health, precision health, population health, women's health, and neurologic health. The company operates as a Nasdaq-listed social innovation platform focused on immune health, precision diagnostics and women's health through programs like Adimune and Pearsanta.
Strategic Profile
Pro stress-test →The company develops AditxtScore that enables individuals to understand, manage, and monitor their immune profiles, and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that mimics the way the body naturally induces tolerance to its tissues. Pearsanta, Aditxt's majority owned precision diagnostics and personalized medicine subsidiary, was advancing toward commercial launch in the second half of 2025 with blood-based tests for Prostate Cancer and Endometriosis.
Competitive Landscape
Pro stress-test →Aditxt operates under license agreements with Loma Linda University and Leland Stanford Junior University, leveraging academic partnerships for credibility. The company competes in the crowded immunology and precision diagnostics markets against larger biotech firms and specialized diagnostic companies, but maintains differentiation through its immune-mapping platform and multi-indication therapeutic pipeline.
Industry Context
Aditxt, Inc. operates in Biopharmaceuticals / Precision Diagnostics.
Key facts
Founded: 2017 · Headquarters: Mountain View, California · Revenue: $3K · Market cap: $60.4K